Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Toxicity: Risk factors

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...

Drug toxicity: Idiosyncratic Reactions

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

Drug Toxicity: Overview

Drug Toxicity: Overview

Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...

Teratogenicity

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...

Drug Toxicity: Allergic Reactions

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Hydroxyurea (hydroxycarbamide) use in adults with haemoglobin SC disease: A real-world study in Quebec.

British journal of haematology·2026

Same author

Impact of Pharmacist-Provided Education Using New Information Sheets on Activation in Patients Treated with Oral Antineoplastic Drugs (IMPACT-OAD Project).

The Canadian journal of hospital pharmacy·2023

Same author

Management of adverse events related to first-generation tyrosine receptor kinase inhibitors in adults: a narrative review.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2022

Same author

Landscape of coronavirus disease 2019 clinical trials: New frontiers and challenges.

Clinical trials (London, England)·2022

Same author

Effect of mannitol on acute kidney injury induced by cisplatin.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2020

Same author

Opinion, experience and educational preferences concerning pharmacogenomics: an exploratory study of Quebec pharmacists.

Pharmacogenomics·2020

Search research articles

Related Experiment Video

Updated: Jun 1, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Hematologic adverse events associated with temozolomide.

J Lee Villano¹, Nathalie Letarte, Janny M Yu

¹Department of Medicine, Section of Hematology/Oncology, University of Illinois at Chicago, 909 S. Wolcott Ave. Rm. 3133 (M/C 734), Chicago, IL 60612, USA. jvillano@uic.edu

Cancer Chemotherapy and Pharmacology

|May 27, 2011

Summary

Temozolomide (TMZ) can cause severe hematologic adverse events (HAEs), including aplastic anemia (AA), which appears unique among alkylating agents. Patients require disclosure regarding these significant risks.

More Related Videos

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Related Experiment Videos

Last Updated: Jun 1, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Area of Science:

Hematology
Oncology
Pharmacovigilance

Background:

Temozolomide (TMZ) is an oral alkylating agent commonly used in cancer treatment.
Severe hematologic adverse events (HAEs) have been linked to TMZ, but clinical data are limited.

Purpose of the Study:

To investigate the incidence and characteristics of HAEs associated with TMZ.
To identify specific HAEs and their clinical significance based on FDA MedWatch reports.

Main Methods:

Searched the FDA MedWatch database for TMZ reports from November 1997 to September 2008.
Defined and categorized major HAEs (agranulocytosis, aplasia, aplastic anemia, leukemia, MDS, lymphoma) and minor HAEs.

Main Results:

Analyzed 5,127 reports involving 3,490 patients; 112 cases of major HAEs were identified.
Aplastic anemia (AA) or aplasia (76 cases) and leukemia (17 cases) were the most frequent major HAEs.
Bone marrow failure and pancytopenia were significant minor HAEs (325 cases combined).

Conclusions:

TMZ exhibits a distinct hematologic toxicity profile compared to other alkylating agents.
AA is a notable HAE associated with TMZ, potentially developing after short exposure durations.
While the risk of acute myeloid leukemia/myelodysplastic syndrome (AML/MDS) appears low, longer follow-up is needed for definitive assessment.